Diphenylcyclopropenone clinical trials
Also written diphencyprone.
How each study uses diphenylcyclopropenone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the diphenylcyclopropenone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 6
Nicholas Gulati (2) · University of Alabama at Birmingham (1) · Ain Shams University (1) · Rockefeller University (1) · University of Minnesota (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test diphenylcyclopropenone.
- Jun 2027Trem-1 and Ultraviolet Radiation-induced Immune SuppressionEarly Phase 1 · University of Alabama at Birmingham
Studies
Open first, then newest update. How each study uses diphenylcyclopropenone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous MetastasesRecruitingPhase 1Nicholas GulatiNCT05481658Written as Diphencyprone (DPCP)
- Trem-1 and Ultraviolet Radiation-induced Immune SuppressionActive, not recruitingEarly Phase 1University of Alabama at BirminghamNCT05020496Written as Diphenylcyclopropenone (DPCP)
- DPCP for the Treatment of Alopecia AreataTerminatedPhase 3University of MinnesotaNCT03651752Written as Diphenylcyclopropenone (DPCP) Ointment
- DPCP to Treat Cutaneous Neurofibromas Associated With NF1CompletedPhase 1Nicholas GulatiNCT05438290Written as DPCP
- Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive VitiligoCompletedPhase 4Ain Shams UniversityNCT04775979Written as diphenylcyclopropenone (DPCP)
- Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)CompletedPhase 1Rockefeller UniversityNCT01711684Written as Diphenylcyclopropenone (DPCP)
Given beside what is tested · 1 — diphenylcyclopropenone is usual care or a partner of the new treatment
Codes
What other systems call diphenylcyclopropenone · ClinicalTrials.gg INT002892
- MeSH (NLM) C029402diphenylcyclopropenoneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I7G14NW5ECDIPHENCYPRONEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C029402 | diphenylcyclopropenone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I7G14NW5EC | DIPHENCYPRONE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.